Listen
TRAVATAN (travoprost) - Intraocular hypertension or glaucoma
Opinions on drugs -
Posted on
Sep 15 2025
Reason for request
Modification of the listing conditions
Summary of opinion
Favourable opinion for reimbursement in:
- decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma;
- decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.
No clinical added value of the new form compared to the form already available.
Clinical Benefit
| Substantial |
The clinical benefit of TRAVATAN 40 µg/mL (travoprost) eye drops, solution, packaged in a polyethylene bottle, is substantial in the MA indication.
|
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that provides no clinical added value (CAV V) compared to the form already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
